immunology-congress-2018-posters-abstracts

Page 40

allied

academies

Journal of Timely Topics in Clinical Immunology | Volume 2

July 26-28, 2018 | Moscow, Russia

Immunology

Annual Congress on

Innovative Vaccine Strategy against HSV Infections

Aziz Alami Chentoufi

SKLM, Morocco

erpes simplex virus type 1 and type 2 (HSV-1 and HSV-2)

infections would be controlled by the development of an

effective vaccine. However, in spite of several clinical trials,

starting as early as 1920s, no vaccine has been proven suffi-

ciently safe and efficient to warrant commercial development.

Recently, great advances in cellular and molecular immunolo-

gy understanding have stimulated creative approaches in con-

trolling herpes infections and diseases. Before moving towards

novel vaccine strategy, it is required to answer the important

questions: (i) why past herpes vaccines were unsuccessful?

(ii) Why the majority of HSV seropositive individuals naturally

control HSV infections and exhibit few or no recurrent herpet-

ic disease, while few others have frequent herpes clinical ep-

isodes? We recently discovered that HSV-1 symptomatic and

asymptomatic individuals develop distinct immunity to viral

epitopes recognized by CD4+ and CD8+ T cells. These epitopes

(protective vs pathologic) have provided a solid foundation for

the development of novel herpes epitope-based vaccine strate-

gy. In this presentation, I will provide an overviewof past clinical

vaccine trials and outline current progress towards developing

a new generation “asymptomatic” clinical herpes vaccines and

discuss future mucosal “asymptomatic” prime-boost vaccines

that could optimize the protective immunity.